Verteporfin protects against Th17 cell‐mediated EAE independently of YAP inhibition
Please always quote using this URN: urn:nbn:de:bvb:20-opus-287234
- The known YAP inhibitor verteporfin is capable of repressing IL‐17A production in Th17 cells. However, this effect is mediated independently of YAP and can ameliorate Th17‐mediated experimental autoimmune encephalomyelitis (EAE) upon in vivo administration. The data suggest verteprofin's mode of action for the design of novel therapeutic autoimmune disease intervention.
Author: | Paulin Brosinsky, Hanna Leister, Nan Cheng, Xaralabos Varelas, Alexander Visekruna, Maik Luu |
---|---|
URN: | urn:nbn:de:bvb:20-opus-287234 |
Document Type: | Journal article |
Faculties: | Medizinische Fakultät / Medizinische Klinik und Poliklinik II |
Language: | English |
Parent Title (English): | European Journal of Immunology |
Year of Completion: | 2022 |
Volume: | 52 |
Issue: | 9 |
First Page: | 1523 |
Last Page: | 1526 |
Source: | European Journal of Immunology 2022, 52(9):1523–1526. DOI: 10.1002/eji.202149564 |
DOI: | https://doi.org/10.1002/eji.202149564 |
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Tag: | EAE; Hippo signaling; Th17 cells; YAP; verteporfin |
Release Date: | 2023/01/18 |
Licence (German): | CC BY-NC: Creative-Commons-Lizenz: Namensnennung, Nicht kommerziell 4.0 International |